BCLSI
ALKS icon

Bain Capital Life Sciences Investors’s Alkermes ALKS Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ALKS Stock Details ALKS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Buy
1,937,938
+1,327,938
+218% +$51.9M 6.04% 5
2026
Q1 		$21.6M Buy
+610,000
New +$18.9M 1.95% 13

Other funds holding ALKS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bain Capital Life Sciences Investors's ALKS Position: Q2 2026 in Review

Bain Capital Life Sciences Investors increased its Alkermes (ALKS) stake by 218% in Q2 2026, buying an estimated $51.9M and bringing the position to 1,937,938 shares worth $102M. The position accounts for 6.04% of the portfolio, ranked #5.

Bain Capital Life Sciences Investors first reported a position in ALKS in Q1 2026 and has held it in 2 quarters since. 424 funds tracked by Wall St. Rank hold ALKS as of Q2 2026.

  • Bain Capital Life Sciences Investors held 1,937,938 shares of Alkermes worth $102M as of Q2 2026.
  • Bain Capital Life Sciences Investors bought 1,327,938 Alkermes shares in Q2 2026, an estimated $51.9M.
  • Alkermes made up 6.04% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #5 holding.
  • Bain Capital Life Sciences Investors first reported a position in Alkermes in Q1 2026 and has held it in 2 quarters since.
  • 424 funds tracked by Wall St. Rank held Alkermes as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.